CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.
  
  LEARNING OBJECTIVES

  • Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
  • Evaluate the mechanisms of action of and available clinical trial findings with bispecific antibodies targeting CD20 x CD3 in patients with FL, and determine the role of these agents in current clinical management.
  • Consider patient age, performance status and other clinical and biological factors to optimize up-front and subsequent treatment of mantle cell lymphoma (MCL).
  • Review available research findings with Bruton tyrosine kinase (BTK) inhibitors as a component of induction therapy for MCL, and assess the risks and potential benefits of this strategy for patients who are eligible and not eligible for autologous stem cell transplant.
  • Discuss available clinical research findings demonstrating the efficacy and safety of noncovalent BTK inhibitors in patients with MCL, and use this information to evaluate the current role of these agents in therapy for R/R disease.
  • Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor T-cell therapy for R/R FL and MCL, and counsel appropriately selected patients regarding the potential benefits of this strategy.
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Recall new data with agents and strategies currently under investigation for FL, MCL and HL, and consider the roles these may soon play, in addition to ongoing trial opportunities for eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ASHLymphoma23/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jeremy S Abramson, MD, MMSc
  Director, Center for Lymphoma
  Massachusetts General Hospital
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Caribou Biosciences Inc, Cellectar Biosciences Inc, Century Therapeutics, Epizyme Inc, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Interius BioTherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol Myers Squibb, Cellectis, Merck, Mustang Bio, Seagen Inc.
  
  Stephen M Ansell, MD, PhD
  Chair, Division of Hematology
  Dorotha W and Grant L Sundquist Professor in Hematologic Malignancies Research
  Enterprise Deputy Director, Mayo Clinic Cancer Center
  Mayo Clinic in Rochester, Minnesota
  Rochester, Minnesota
  
  Contracted Research: ADC Therapeutics, Affimed, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Pfizer Inc, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.
  
  Nancy L Bartlett, MD
  Professor of Medicine
  Koman Chair in Medical Oncology
  Washington University School of Medicine
  St Louis, Missouri
  
  Advisory Committee: ADC Therapeutics, Foresight Diagnostics, Genentech, a member of the Roche Group, Kite, A Gilead Company; Contracted Research: ADC Therapeutics, Autolus Therapeutics, Bristol Myers Squibb, Celgene Corporation, Forty Seven Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc , Kite, A Gilead Company, Merck, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Takeda Pharmaceuticals USA Inc.
  
  Jonathon B Cohen, MD
  Associate Professor, Hematology and Medical Oncology
  Co-Director, Lymphoma Program
  Emory University Winship Cancer Institute
  Atlanta, Georgia
  
  Advisory Committee: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, HUTCHMED, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: AI Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Takeda Pharmaceuticals USA Inc.
  
  Jonathan W Friedberg, MD, MMSc
  Samuel E Durand Professor of Medicine
  Director, James P Wilmot Cancer Institute
  University of Rochester
  Rochester, New York
  
  No relevant conflicts of interest to disclose.
  
  Brad S Kahl, MD
  Professor of Medicine
  Washington University School of Medicine
  Director, Lymphoma Program
  Siteman Cancer Center
  St Louis, Missouri
  
  Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Novartis, Roche Laboratories Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc and AbbVie Inc, Merck, and Seagen Inc.
  
  Release date: December 2023
  Expiration date: December 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.